Abstract:Abstract The elderly and those with chronic diseases have a 2 to 10-fold increased risk of hospitalization and mortality following infection as compared with healthy adults. A significant contributor to disease severity is the aging of the immune system, including an expansion of exhausted T cells. These cells simultaneously promote excessive levels of inflammation and display impaired T cell activation and function. How exhausted T cells from aged individuals respond to infection and whether acute restoration of T cell activation further exacerbates the inflammatory environment or generates functional T cells is unclear. Previously, we used a mouse model of normal microbial exposure (NME), where old specific pathogen-free (SPF) mice show 100% mortality following exposure to multiple microbes ordinarily found in pet store mice. In the present study, we show that when exposed to NME, old SPF mice have increased expression of multiple inflammatory pathways and exhibit elevated frequencies of a heterogenous, exhausted CD8 +T cell pool that expresses differing combinations of programmed cell death protein 1 (PD1), TOX, and CXCR5. Pre-treatment or intervention with an anti-PD1 monoclonal blocking antibody during the exposure of old SPF mice to NME significantly improves both antibody production and survival, without altering the acute inflammatory response. Anti-PD1 checkpoint blockade-mediated survival is dependent on CD8 +, but not CD4 +T cells. Correspondingly, CD8 +PD1 +T cells from old mice given anti-PD1 monoclonal antibody have increased granzyme B production. These data reveal a new approach for reducing vulnerability to infections in the elderly by targeting CD8 +T cell exhaustion through PD1 checkpoint blockade immunotherapy. This work was supported by National Institute on Aging grant R00 AG058800 (C.D.C.), R21AG078638, the Fesler-Lampert Chair in Aging Studies, the Glenn Foundation for Medical Research/AFAR Grants for Junior Faculty, Irene Diamond Fund/AFAR Postdoctoral Transition Award (M.J.Y) and the Medical Discovery Team on the Biology of Aging.

Upregulation of PD-L1 in Senescence and Aging

p16-dependent increase of PD-L1 stability regulates immunosurveillance of senescent cells

The role of the immunosuppressive PD-1/PD-L1 checkpoint pathway in the aging process and age-related diseases

Blocking PD-L1-PD-1 improves senescence surveillance and ageing phenotypes

Aged alveolar epithelium contributes to inflammaging and reduced stem cell function in the lung

Prolonged WNT/ß-catenin signaling induces cellular senescence in aging and pulmonary fibrosis

Upregulated PD-1 Signaling is an Important Antagonist to Glomerular Health in Aged Kidneys

Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD‐L1)‐mediated immunosuppression

Role of Cellular Senescence in Inflammatory Lung Diseases

Impaired immune surveillance accelerates accumulation of senescent cells and aging

Increased CD47 and MHC Class I Inhibitory Signals Expression in Senescent CD1 Primary Mouse Lung Fibroblasts

The Role of Aging and Senescence in Immune Checkpoint Inhibitor Response and Toxicity

PD1 blockade improves survival during lethal microbial exposure in old mice

[Current Status and Prospect of PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy in Elderly Patients with Advanced NSCLC]

PD-1 regulation in immune homeostasis and immunotherapy

STING mediates nuclear PD-L1 targeting-induced senescence in cancer cells

Senescence-induced endothelial phenotypes underpin immune-mediated senescence surveillance

Senescent cells: SASPected drivers of age-related pathologies

An updated immunosenescence exploration in healthy Chinese donors: circular elevated PD-1 on T cell and increased Ki67 on CD8+ T cell towards aging

Regulation of Cellular Senescence by Innate Immunity.

T cell senescence: a new perspective on immunotherapy in lung cancer